Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
39.13
0.00 (0.00%)
At close: Apr 22, 2024, 12:00 AM
41.08
+1.95 (4.98%)
Pre-market: Apr 23, 2024, 9:09 AM EDT
Vera Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vera Therapeutics stock have an average target of 32.29, with a low estimate of 22 and a high estimate of 56. The average target predicts a decrease of -17.48% from the current stock price of 39.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for VERA stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +43.11% | Apr 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $27 → $56 | Strong Buy | Maintains | $27 → $56 | +43.11% | Mar 27, 2024 |
| Wedbush | Wedbush | Hold Maintains $21 → $34 | Hold | Maintains | $21 → $34 | -13.11% | Mar 21, 2024 |
| Wedbush | Wedbush | Hold Maintains $16 → $21 | Hold | Maintains | $16 → $21 | -46.33% | Jan 26, 2024 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $29 → $37 | Buy → Strong Buy | Upgrades | $29 → $37 | -5.44% | Jan 26, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.20
from -2.25
EPS Next Year
-2.37
from -2.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 85.8M | 323.0M | 653.0M |
| Avg | n/a | n/a | 41.6M | 146.5M | 367.8M |
| Low | n/a | n/a | 7.7M | 68.5M | 219.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 676.7% | 345.8% |
| Avg | - | - | - | 252.2% | 151.1% |
| Low | - | - | - | 64.7% | 49.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.08 | -1.94 | -2.25 | -0.17 | 2.70 |
| Avg | -2.20 | -2.37 | -2.71 | -0.65 | 1.43 |
| Low | -2.57 | -3.11 | -3.33 | -1.39 | 0.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.